[ad_1]
London, July 6, 2021 (GLOBE NEWSWIRE) – NVIDIA today officially launched Cambridge-1, the UK’s most powerful supercomputer, which will enable top scientists and healthcare professionals to use the powerful combination of artificial intelligence and simulation to accelerate digital The biological revolution and support the country’s world-leading life science industry.
Cambridge-1 is committed to advancing healthcare and is a $100 million investment from NVIDIA. Its first project in collaboration with AstraZeneca, GlaxoSmithKline, Gay and St. Thomas’ NHS Foundation Trust, King’s College London and Oxford Nanopore Technology Inc. included in-depth understanding of brain diseases such as dementia, and the use of artificial Intelligently design new drugs and improve the accuracy of discovering pathogenic factors. Variations in the human genome.
Cambridge-1 brings together NVIDIA’s decades of work in accelerated computing, artificial intelligence, and life sciences. Nvidia Clara™ and AI frameworks are optimized to use the entire system for large-scale research.One NVIDIA DGX SuperPOD™ Supercomputing cluster, which ranks among the top 50 fastest computers in the world and is powered by 100% renewable energy.
“Cambridge-1 will enable the world’s leading business and academic researchers to complete their life’s work on the UK’s most powerful supercomputer, unlocking clues to diseases and treatments at an unprecedented scale and speed,” Jensen Huang said. Founder and CEO of Nvidia. “The discoveries developed on Cambridge-1 will take shape in the United Kingdom, but their impact will be global, promoting groundbreaking research and potentially benefiting millions of people around the world.”
Cambridge-1 builds on the UK’s status as a global leader in life sciences, technology and artificial intelligence, providing contemporary and future generations with advanced infrastructure to carry out groundbreaking research in the country.
According to a report by economic consulting firm Frontier Economics, Cambridge-1 has the potential to create an estimated value of 600 million pounds (approximately US$825 million) in the next 10 years.
AstraZeneca: Using artificial intelligence to change drug discovery
NVIDIA is working with AstraZeneca to speed up drug discovery by creating a generative AI model based on a converter for chemical structures. The Transformer-based neural network architecture has only been available in recent years, and it allows researchers to use self-supervised training methods to utilize large data sets and avoid manually labeling examples during pre-training.
The MegaMolBART drug discovery model is being used for reaction prediction, molecular optimization and de novo molecular generation, and will optimize the drug development process. It is based on AstraZeneca’s MolBART transformer model and is being trained on the ZINC compound database-using NVIDIA’s Megatron framework to achieve large-scale training of supercomputing infrastructure.This open source model will be provided to researchers and developers NVIDIA NGC™ Software Catalog.
Nvidia and AstraZeneca have a separate project on Cambridge-1 that focuses on the use of artificial intelligence in digital pathology. In digital pathology, a lot of time and money are spent annotating entire slide images of tissue samples to help find new insights. By using unsupervised AI algorithms trained on thousands of images, the annotation process can be eliminated while finding potential imaging features related to drug response.
“Training artificial intelligence algorithms on the entire slide image is challenging, in part because of the size of the image,” said Lindsay Edwards, vice president of data science and artificial intelligence, respiratory and immunology, AstraZeneca Biopharmaceuticals R&D. “Working with NVIDIA on Cambridge-1 allows us to extend our current work and develop new methods to advance the use of artificial intelligence in digital pathology.”
GlaxoSmithKline: Lead great science with partners…
The full story on Benzinga.com
[ad_2]
Source link
